Managers / Q1 2026
DIADEMA PARTNERS LP
CIK 0002026172 · 2140 HEADQUARTERS PLAZA, EAST TOWER, 2ND FLOOR, MORRISTOWN, NJ, 07960 · 917-513-8539
Reported Value
$588M
Q1 2026
Positions
144
Filings on Record
6
2019–present window
Filed
May 15, 2026
original filing
Summary
Diadema Partners Lp reported $588M in U.S.-listed holdings across 144 positions for Q1 2026.
Its largest position, Bridgebio Pharma, represents 3.2% of the portfolio.
Compared with Q4 2025, the fund opened 44 new positions and exited 52.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 80.9% · $475M
- ADR · 9.0% · $53M
- Other · 7.0% · $41M
- US DOMESTIC · 3.2% · $19M
Quarter-over-Quarter Changes full breakdown →
Holdings — Q1 2026
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $588M | 144 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $581M | 145 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $391M | 130 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $328M | 96 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $383M | 102 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $233M | 107 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.